Condition (MeSH)
Multiple Endocrine Neoplasia Type 1
ClinicalTrials.gov lists 191 trials for Multiple Endocrine Neoplasia Type 1 or a narrower condition beneath it. Bayer has the most among industry and government lead sponsors, with 12.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
191 of the 191 trials are tagged with Multiple Endocrine Neoplasia Type 1 itself; the rest are tagged with a narrower condition beneath it.
When did Multiple Endocrine Neoplasia Type 1 trials start? (27)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 21
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 9 |
| 2024 | 9 |
| 2023 | 10 |
| 2022 | 11 |
| 2021 | 21 |
| 2020 | 11 |
| 2019 | 7 |
| 2018 | 11 |
| 2017 | 10 |
Showing 10 of 27 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 7 trials starting in 2026 and about 8 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 11 trials still running at the 2026-10-09 snapshot; registered median of 21 months across 140 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Multiple Endocrine Neoplasia Type 1 trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 22 |
| Phase 1/2 | 4 |
| Phase 2 | 13 |
| Phase 2/3 | 3 |
| Phase 3 | 9 |
| Phase 4 | 9 |
| Not applicable | 100 |
| Observational | 31 |
How many Multiple Endocrine Neoplasia Type 1 trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 12 |
| Enrolling by invitation | 3 |
| Active, not recruiting | 8 |
| Completed | 137 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Multiple Endocrine Neoplasia Type 1 trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Bayer | 12 |
| Novartis Pharmaceuticals | 5 |
| National Cancer Institute (NCI) | 3 |
| Amgen | 2 |
| GlaxoSmithKline | 2 |
Which drugs are being tested for Multiple Endocrine Neoplasia Type 1? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Elinzanetant | 11 |
| FULVESTRANT | 4 |
| Ribociclib | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Alpelisib Pill | 3 |
| Letrozol (Femara, Novartis) | 2 |
| Standard Care | 2 |
| PYY1-36 infusion | 1 |
| fezolinetant - reference formulation | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Multiple Endocrine Neoplasia Type 1 trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Angina unstable | 198 | 1 |
| Angina pectoris | 186 | 3 |
| Coronary artery disease | 182 | 1 |
| COVID-19 pneumonia | 170 | 2 |
| Osteoarthritis | 169 | 3 |
Showing 5 of 10 adverse events.
Which publications cover Multiple Endocrine Neoplasia Type 1? (29)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Genotype-phenotype correlation in multiple endocrine neoplasia type 1. | JCI insight | 2025 | Yes |
| Cancer statistics, 2023. | CA: a cancer journal for clinicians | 2023 | Yes |
| The clinical aspects of pituitary tumour genetics. | Endocrine | 2021 | Yes |
| 68Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1. | The Journal of clinical endocrinology and metabolism | 2019 | Yes |
| Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database. | Endocrine | 2018 | Yes |
Showing 5 of 29 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Multiple endocrine neoplasia type 1 | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Exact |
| Multiple endocrine neoplasia type 1 | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Exact |
| Multiple endocrine neoplasia type 1 | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Unspecified |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Multiple endocrine neoplasia type 1 | 652 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Multiple endocrine neoplasia type 1 | 652 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.